The new face of fighting cancer
The battle against cancer has raged for decades and the end game is nearing. Merus’ innovative bispecific antibody therapeutics referred to as Biclonics® are designed to recruit the immune system to kill cancer cells and tip the balance in favor of patients with more effective treatments that have less side effects. Ultimately, it is Merus’ goal to help declare victory for patients with this devastating disease to help them lead normal lives.
Read moreProduct Candidates
Human Biclonics®
Biclonics® are designed to possess a format of antibodies that are produced naturally by the immune system, and are designed to retain their favorable attributes including stability, predictability during manufacturing, long half-life and low immunogenicity during treatment of patients.
Read moreThe new face of fighting cancer
Upcoming events
Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.
All eventsMerus to Present at PEGS (The Essential Protein Engineering Summit)
PEGS: The Essential Protein Engineering Summit is one of the industry’s most preeminent events that inspires accelerated biotherapeutic protein drug development. This weeklong event attracts over...
Read More